Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

FHS
August 30, 2023
12:05 pm

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.

Doctors advocate fresh efforts to combat Chagas disease, a silent killer

When Maira Gutiérrez was diagnosed with Chagas disease in 1997, neither she nor her primary care physician had even heard of the malady. She discovered

August 22, 2023

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK – Biotech Investments

Issuer: CureVac / Key word(s): Study results 04.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Promising

April 5, 2024

As wildfires burn, scientists race to understand the health dangers of prolonged exposure

More than 120 million Americans — one-third of the U.S. population — have been living under air quality alerts this summer, with citizens in New

July 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.